Gloucestershire Royal Hospital is an acute District General Hospital on the Great Western Road in Gloucester operated by the Gloucestershire Hospitals NHS Foundation Trust.
ABSTRACT Key Content Early pregnancy presentations form a large part of unscheduled hospital attendance, with miscarriage affecting one in four pregnancies. The self‐sufficiency of many Early Pregnancy Assessment Units (EPAUs) can reduce exposure for obstetrics and gynaecology doctors to counselling patients and formulating ongoing management plans. Interpreting scan findings and their significance can be difficult when this is not part of a daily workload. Patients are often anxious and providing support whilst navigating diagnostic uncertainty can be challenging. This article reviews the up‐to‐date evidence for managing early pregnancy problems that the on‐call doctor, particularly when working out of hours, may encounter and clarify ultrasound scan terminology to improve confidence when managing these patients. Learning Objectives To improve confidence in counselling early pregnancy patients about the management of pregnancy of unknown location, pregnancy of uncertain viability, miscarriage and confirmed ectopic pregnancy. To understand the significance of ultrasound findings, including normal findings, by gestational age and to convey this information to patients. To understand the impact of early pregnancy concerns on patients and signpost to appropriate support services. Ethical Issues Misdiagnosis of miscarriage. Delayed diagnosis of miscarriage. Variable access to ultrasound (both equipment and trained users) during out‐of‐hours.
Abstract Vulvovaginal mucosal melanomas (VVMMs) affect 1.6 individuals per million per year. Patients frequently present with advanced disease and have poor outcomes. As VVMMs are rare, there is a paucity of high-quality evidence on which to base treatment strategies. This study aimed to describe the clinical course and outcomes for patients diagnosed with VVMM and audit the service provided in our tertiary referral centre. In total, 18 cases of VVMM were identified from 358 records of patients diagnosed with vulvovaginal cancer between January 2015 and September 2025. Treatment course and patient outcomes were compared with standards set out by Melanoma Focus for ano-uro-genital mucosal melanoma. Fifteen patients (83%) were first assessed in a gynaecology urgent suspected cancer clinic, and 15 (83%) underwent a diagnostic biopsy prior to surgical resection. Seventeen (94%) had invasive disease at presentation and 50% had an initial Breslow thickness ≥ 4 mm. Overall, 78% had features of both melanoma in situ and invasive disease. Lateral margins following excision were involved in 53%, predominantly with in situ disease. When next-generation sequencing was performed, KIT mutations were identified in 17% (n = 2). Most patients underwent staging investigations including computed tomography (CT) of the thorax, abdomen and pelvis, and CT of the head (93%). Adjuvant treatments included dacarbazine chemotherapy (n = 1), radiotherapy (n = 3) and immunotherapy (n = 8). Five (28%) of the 18 patients were deceased at the point of data collection. One-quarter of patients (2 of 8, 25%) who received immunotherapy did not survive, compared with 30% (3 of 10) who did not receive immunotherapy; treatment was frequently limited by adverse effects. No patients underwent formal assessment of the impact of VVMM on their quality of life. This study highlights the critical need for further research into optimal management strategies for VVMM, particularly the impact of molecular profiles and relevance of immunotherapy. Studies into the impact of VVMM on quality of life are urgently required. Our team have developed a local standard operating procedure to improve patient management.
Breast cancer is the most common malignancy in women worldwide. A large proportion of breast cancer cases demonstrate human epidermal growth factor receptor 2 (HER2) overexpression. Trastuzumab emtansine (T-DM1) is an established therapy for HER2-positive metastatic breast cancer, though rare but serious adverse effects may occur. We report a 58-year-old woman with HER2-positive metastatic breast cancer who developed progressive exertional dyspnoea while receiving T-DM1. Echocardiography demonstrated right ventricular dilation and dysfunction with elevated pulmonary pressures. Right heart catheterisation confirmed pulmonary arterial hypertension (PAH) with increased pulmonary vascular resistance. Comprehensive evaluation, including computed tomography, pulmonary angiography, and ventilation-perfusion scanning, excluded thromboembolic disease. There was no significant parenchymal lung disease, and left ventricular function was preserved. In the absence of alternative causes and given the temporal relationship with T-DM1 exposure, drug-induced PAH was considered likely. The patient was treated with sildenafil and ambrisentan, resulting in symptomatic and haemodynamic improvement. Concurrent hepatotoxicity also resolved following discontinuation of T-DM1, further supporting a causal association. PAH is a rare complication of HER2-targeted therapies, with limited cases reported. This case highlights the importance of recognising PAH as a potential adverse effect of T-DM1. Clinicians should maintain a high index of suspicion in patients presenting with unexplained dyspnoea or right ventricular dysfunction to enable early diagnosis and appropriate management.